Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Better scores needed for predicting advanced fibrosis in nonobese NAFLD patients

Tristan Manalac
25 Jun 2020

There is a need to develop a better predictive tool for detecting nonobese patients with nonalcoholic fatty liver disease (NAFLD) at risk of advanced fibrosis, according to a new Singapore study.

“Fibrosis-4 (FIB4) remains the most accurate noninvasive score in predicting fibrosis. However, the application of noninvasive scores on nonobese patients needs to be interpreted within its clinical context,” researchers said. “Noninvasive scores are not fully reliable in predicting fibrosis in the nonobese population.”

The researchers enrolled 263 NAFLD patients, of whom 206 (mean age, 49.5±12.5 years; 53.9 percent male) had body mass index (BMI) 25 kg/m2 and were categorized as obese; the remaining 57 (mean age, 54.0±12.9 years; 47.4 percent male) had BMI <25 kg/m2. Almost half of the participants had diabetes mellitus, and majority had hypertension and dyslipidaemia. [J Gastroenterol Hepatol 2020;doi:10.1111/jgh.15154]

Bilirubin was higher in nonobese patients (p=0.02), as was prothrombin time (p=0.025). In comparison, albumin (p=0.018) and platelet count (p<0.001) were both reduced in this subgroup.

In contrast, both groups were statistically comparable in terms of median NAFLD activity score (NAS; 4 vs 4) and other histological characteristics, such as lobular inflammation, steatosis grade, and ballooning. The prevalence of nonalcoholic steatohepatitis (NASH) was likewise similar between patient subgroups (61.4 percent vs 63.1 percent; p=0.710). The same was true for advanced fibrosis (26.3 percent vs 31.6 percent; p=0.447).

Of all the noninvasive scores employed, FIB4 at a cut-off value of >3.25 showed the best predictive power for advanced fibrosis in the study sample. The resulting area under the receiver-operator characteristic curve (AUROC) was 0.68. This was even better in obese patients, with an AUROC of 0.78.

Notably, all three noninvasive scores (FIB4, NAFLD fibrosis score, aspartate aminotransferase-to-platelet ratio) performed worse in nonobese patients than in their obese comparators.

The same was true for the other measures of predictive performance. FIB4 sensitivity, for example, was better in those who were obese (0.66 vs 0.60), as was its specificity (0.72 vs 0.48). A similar pattern of effect was observed for FIB4’s positive (0.54 vs 0.30) and negative (0.82 vs 0.76) predictive values.

The two other noninvasive scores were less powerful than FIB4 but nevertheless reflected the discrepancy associated with obesity.

“Within the limitations of our biopsy cohort, nonobese patients with NASH may have a similar propensity for advanced fibrosis as obese patients,” the researchers said. “This underscores the clinical significance of nonobese NASH and concurrently highlights the lack of understanding of antecedent factors both common and disparate in obese and nonobese NASH.”

“This may further give impetus to investigate and treat nonobese patients with NAFLD/NASH as aggressively as obese patients, given their potentially equal propensity for progression to advanced disease,” they added.

Moreover, the researchers said that their findings highlight “an unmet need for developing/optimizing nonobese NASH specific noninvasive scores to screen for advanced fibrosis in a population that is often poorly recognized.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.